LPAR3

Summary

LPAR3 (lysophosphatidic acid receptor 3, HGNC:14298) is a protein-coding gene on chromosome 1p22.3, encoding Lysophosphatidic acid receptor 3 (Q9UBY5). Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities.

This gene encodes a member of the G protein-coupled receptor family, as well as the EDG family of proteins. This protein functions as a cellular receptor for lysophosphatidic acid and mediates lysophosphatidic acid-evoked calcium mobilization. This receptor couples predominantly to G(q/11) alpha proteins.

Source: NCBI Gene 23566 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 69 total
• Expression (HPA): Tissue enhanced — highest in fallopian tube, area postrema, dorsal motor vagal complex
• GTEx eGene: eQTL in 27 tissues, sQTL in 1 (q < 0.05)
• Constraint (gnomAD): pLI 0.78 (intermediate), LOEUF 0.62 (unconstrained)
• MANE Select transcript: NM_012152
• Notable: 69 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14298
Approved symbol	LPAR3
Name	lysophosphatidic acid receptor 3
Location	1p22.3
Locus type	gene with protein product
Status	Approved
Aliases	LP-A3, Edg-7, RP4-678I3, HOFNH30, LPA3
Ensembl gene	ENSG00000171517
Ensembl biotype	protein_coding
OMIM	605106
Entrez	23566

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 13 protein_coding, 1 protein_coding_CDS_not_defined

MANE Select: ENST00000370611

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 3: 1

ENST00000370611, ENST00000440886, ENST00000491034, ENST00000930963, ENST00000930964, ENST00000930965, ENST00000930966, ENST00000942299, ENST00000942300, ENST00000942301, ENST00000942302, ENST00000942303, ENST00001028116, ENST00001145346

RefSeq mRNA: 1 — MANE Select: NM_012152 NM_012152

CCDS: CCDS700

Canonical transcript exons

ENST00000370611 — 3 exons

Exon	Start	End
ENSE00001672580	84893016	84893206
ENSE00001720988	84865385	84866138
ENSE00003891730	84811602	84814171

Expression profiles

Bgee: expression breadth ubiquitous, 170 present calls, max score 95.10.

FANTOM5 (CAGE): breadth broad, TPM avg 1.0747 / max 38.1654, expressed in 389 samples.

Highest expression (Bgee): bronchial epithelial cell, uterine tube, epithelium of bronchus, bronchus, mucosa of paranasal sinus.

Genetic regulation across tissues (GTEx eQTL / sQTL)

LPAR3 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 27 tissues and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 28 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Cells Cultured fibroblasts	eqtl	4.8e-52	+0.44	1:84883501:T:C
Cells EBV-transformed lymphocytes	eqtl	1.4e-34	+1.00	1:84926641:C:T
Whole Blood	eqtl	7.1e-23	+0.49	1:84893289:C:T
Lung	eqtl	4.1e-16	-0.31	1:84873395:C:T
Spleen	eqtl	2.7e-14	+0.85	1:84926641:C:T
Esophagus Mucosa	eqtl	3.7e-12	-0.27	1:84888880:G:A
Skin Sun Exposed Lower leg	eqtl	9.4e-09	+0.24	1:84842841:T:G
Brain Cerebellar Hemisphere	eqtl	4.5e-08	+0.51	1:84777740:G:T
Skin Not Sun Exposed Suprapubic	eqtl	5.8e-07	+0.26	1:84842841:T:G
Brain Cerebellum	eqtl	1.0e-05	+0.41	1:84776811:C:T
Brain Cortex	eqtl	1.7e-05	+0.31	1:84761787:G:C
Brain Hippocampus	eqtl	2.4e-05	+0.35	1:84755059:C:CGT
Brain Anterior cingulate cortex BA24	eqtl	3.1e-05	+0.35	1:84761787:G:C
Small Intestine Terminal Ileum	eqtl	2.7e-04	+0.55	1:84926641:C:T
Brain Frontal Cortex BA9	eqtl	4.1e-04	+0.26	1:84762642:C:T
Minor Salivary Gland	eqtl	1.1e-03	+0.65	1:84842841:T:G
Colon Transverse	eqtl	1.2e-03	+0.19	1:84893414:G:A
Stomach	eqtl	1.8e-03	+0.29	1:84882814:T:G
Testis	eqtl	3.1e-03	+0.12	1:84873395:C:T
Thyroid	eqtl	6.1e-03	+0.21	1:84887029:T:A

FANTOM5 promoters

1 alternative TSS:

Promoter ID	TPM avg	Samples expressed
13011	1.0747	389

Top tissues by expression

showing 100 of 258 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bronchial epithelial cell	CL:0002328	95.10	gold quality
right uterine tube	UBERON:0001302	91.83	gold quality
epithelium of bronchus	UBERON:0002031	90.03	gold quality
bronchus	UBERON:0002185	89.18	gold quality
mucosa of paranasal sinus	UBERON:0005030	88.57	gold quality
dorsal root ganglion	UBERON:0000044	85.67	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	85.10	gold quality
trigeminal ganglion	UBERON:0001675	81.63	gold quality
cardiac atrium	UBERON:0002081	81.52	gold quality
right atrium auricular region	UBERON:0006631	81.49	gold quality
myocardium	UBERON:0002349	80.62	silver quality
cardiac muscle of right atrium	UBERON:0003379	79.88	silver quality
oviduct epithelium	UBERON:0004804	79.33	gold quality
fallopian tube	UBERON:0003889	78.82	gold quality
body of pancreas	UBERON:0001150	78.72	gold quality
endometrium	UBERON:0001295	78.10	gold quality
lower esophagus mucosa	UBERON:0035834	77.73	gold quality
urethra	UBERON:0000057	77.01	gold quality
prostate gland	UBERON:0002367	76.94	gold quality
nasal cavity mucosa	UBERON:0001826	76.79	gold quality
epithelium of nasopharynx	UBERON:0001951	76.20	gold quality
heart right ventricle	UBERON:0002080	75.99	silver quality
esophagus mucosa	UBERON:0002469	75.90	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	75.89	gold quality
gingival epithelium	UBERON:0001949	75.70	gold quality
heart left ventricle	UBERON:0002084	74.70	gold quality
cardiac ventricle	UBERON:0002082	74.64	gold quality
gingiva	UBERON:0001828	74.39	gold quality
nasal cavity epithelium	UBERON:0005384	74.11	silver quality
right testis	UBERON:0004534	73.96	gold quality
esophagus squamous epithelium	UBERON:0006920	73.72	gold quality
heart	UBERON:0000948	73.37	gold quality
squamous epithelium	UBERON:0006914	73.25	gold quality
testis	UBERON:0000473	72.98	gold quality
epithelium of esophagus	UBERON:0001976	72.87	gold quality
pancreas	UBERON:0001264	72.68	gold quality
left testis	UBERON:0004533	72.43	gold quality
stromal cell of endometrium	CL:0002255	72.01	gold quality
cauda epididymis	UBERON:0004360	71.68	gold quality
skin of hip	UBERON:0001554	71.66	gold quality
corpus epididymis	UBERON:0004359	71.18	gold quality
diaphragm	UBERON:0001103	71.06	gold quality
skin of abdomen	UBERON:0001416	70.78	gold quality
apex of heart	UBERON:0002098	70.35	gold quality
tibia	UBERON:0000979	69.99	gold quality
mouth mucosa	UBERON:0003729	69.91	gold quality
minor salivary gland	UBERON:0001830	69.68	gold quality
zone of skin	UBERON:0000014	69.56	gold quality
saliva-secreting gland	UBERON:0001044	69.13	gold quality
cervix squamous epithelium	UBERON:0006922	69.09	gold quality
skin of leg	UBERON:0001511	69.04	gold quality
vagina	UBERON:0000996	69.03	gold quality
upper leg skin	UBERON:0004262	68.10	gold quality
oral cavity	UBERON:0000167	68.07	silver quality
palpebral conjunctiva	UBERON:0001812	67.83	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	67.41	gold quality
tonsil	UBERON:0002372	66.41	gold quality
mammalian vulva	UBERON:0000997	65.80	silver quality
urinary bladder	UBERON:0001255	65.70	gold quality
trachea	UBERON:0003126	65.05	silver quality
upper arm skin	UBERON:0004263	64.99	gold quality
seminal vesicle	UBERON:0000998	64.86	silver quality
right frontal lobe	UBERON:0002810	64.71	gold quality
islet of Langerhans	UBERON:0000006	64.44	gold quality
vastus lateralis	UBERON:0001379	64.41	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	64.38	gold quality
right adrenal gland cortex	UBERON:0035827	64.20	gold quality
quadriceps femoris	UBERON:0001377	64.08	gold quality
prefrontal cortex	UBERON:0000451	64.00	gold quality
anterior cingulate cortex	UBERON:0009835	63.59	gold quality
cingulate cortex	UBERON:0003027	63.55	gold quality
pharyngeal mucosa	UBERON:0000355	63.45	silver quality
Ammon’s horn	UBERON:0001954	63.30	gold quality
penis	UBERON:0000989	62.90	silver quality
dorsolateral prefrontal cortex	UBERON:0009834	62.83	gold quality
frontal cortex	UBERON:0001870	62.80	gold quality
mucosa of transverse colon	UBERON:0004991	62.61	gold quality
Brodmann (1909) area 9	UBERON:0013540	62.61	gold quality
periodontal ligament	UBERON:0008266	62.41	gold quality
female reproductive system	UBERON:0000474	62.36	gold quality
superficial temporal artery	UBERON:0001614	62.29	gold quality
right lung	UBERON:0002167	62.23	gold quality
neocortex	UBERON:0001950	61.96	gold quality
cerebral cortex	UBERON:0000956	61.81	gold quality
hair follicle	UBERON:0002073	61.79	gold quality
body of tongue	UBERON:0011876	61.79	gold quality
mucosa of urinary bladder	UBERON:0001259	61.67	gold quality
caput epididymis	UBERON:0004358	61.55	silver quality
vena cava	UBERON:0004087	61.42	gold quality
uterus	UBERON:0000995	61.09	gold quality
saphenous vein	UBERON:0007318	60.99	gold quality
olfactory bulb	UBERON:0002264	60.97	gold quality
inferior vagus X ganglion	UBERON:0005363	60.85	gold quality
lower lobe of lung	UBERON:0008949	60.82	silver quality
dorsal plus ventral thalamus	UBERON:0001897	60.81	gold quality
type B pancreatic cell	CL:0000169	60.73	gold quality
pericardium	UBERON:0002407	60.69	gold quality
lateral globus pallidus	UBERON:0002476	60.64	gold quality
substantia nigra pars reticulata	UBERON:0001966	60.50	gold quality
subthalamic nucleus	UBERON:0001906	60.42	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.67
E-GEOD-124858	no	1.47

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 72 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM
Fallopian tube	tissue	34.2
Prostate	tissue	12.6
Cervix	tissue	9.8
Pancreas	tissue	9.8
Testis	tissue	9.7
Heart muscle	tissue	8.8
Postcentral gyrus	tissue	7.2
Hippocampus	tissue	6.4
Epididymis	tissue	5.6
Salivary gland	tissue	5.4
Vagina	tissue	5.3
Urinary bladder	tissue	4.7
Nucleus accumbens	tissue	4.7
Esophagus	tissue	4.2
Skin 1	tissue	3.7
Choroid plexus	tissue	3.3
Endometrium 1	tissue	2.7
Locus coeruleus	tissue	2.3
Thymus	tissue	2.1
Basal ganglia	tissue	1.6
Lung	tissue	1.4
Placenta	tissue	1.3
Adrenal gland	tissue	1.3
Cerebellum	tissue	1.0
Seminal vesicle	tissue	0.9
Putamen	tissue	0.9
Spinal cord	tissue	0.9
Tonsil	tissue	0.9
Breast	tissue	0.8
Cerebral cortex	tissue	0.8
Ventral forebrain	tissue	0.8
Olfactory bulb	tissue	0.8
Retrosplenial cortex	tissue	0.8
Prefrontal cortex	tissue	0.7
Ovary	tissue	0.7
Amygdala	tissue	0.7
Corpus callosum	tissue	0.7
Hippocampal formation	tissue	0.7
Entorhinal cortex	tissue	0.7
Retrosplenial and cingulate cortex	tissue	0.7
Temporal cortex	tissue	0.7
Occipital cortex	tissue	0.7
Insular cortex	tissue	0.7
Motor cortex	tissue	0.6
Medulla oblongata	tissue	0.6
Hypothalamus	tissue	0.6
Septum	tissue	0.6
Somatosensory cortex	tissue	0.6
Rectum	tissue	0.5
Colon	tissue	0.5
Superior colliculi	tissue	0.5
Substantia nigra	tissue	0.5
Gallbladder	tissue	0.5
Periaqueductal gray	tissue	0.5
Pons	tissue	0.4
Skeletal muscle	tissue	0.4
Midbrain	tissue	0.4
Thalamus	tissue	0.4
Stomach 1	tissue	0.3
Bone marrow	tissue	0.3

Brain sub-regions (HPA Brain Atlas): detected in 188; highest nTPM — Area postrema (17.2), Dorsal motor vagal complex (15.9), Nucleus gracilis (9.3), Nucleus tractus solitarii (9.1), Inferior parietal lobule (7.7).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting LPAR3 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

23 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-4465	99.71	72.56	2096
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-5700	99.64	69.88	2280
HSA-MIR-4519	99.48	66.10	859
HSA-MIR-5697	99.39	67.74	1249
HSA-MIR-155-5P	99.35	70.16	1509
HSA-MIR-190B-3P	99.33	68.29	1382
HSA-MIR-4641	99.28	66.64	744
HSA-MIR-3160-5P	99.28	69.07	1938
HSA-MIR-6737-3P	98.95	68.56	1577
HSA-MIR-7157-3P	98.95	68.70	1582
HSA-MIR-5008-3P	98.73	67.50	1433
HSA-MIR-4723-3P	97.67	65.91	1017
HSA-MIR-6769B-3P	97.41	65.53	1036
HSA-MIR-3183	97.40	65.68	978
HSA-MIR-4524B-3P	95.52	64.12	964

Functional genomics

gnomAD constraint: pLI 0.778, LOEUF 0.623, missense Z 1.43 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000370611 — one region, missense o/e 0.86.

Literature-anchored findings (GeneRIF, showing 39)

• demonstrate that two biological fluids, blood plasma and seminal plasma, differentially activate LPA receptors (PMID:12123830)
• results suggested that lysophosphatidic acid (LPA) receptors LPA(2) and LPA(3) may be involved in VEGF expression mediated by LPA signals in human ovarian oncogenesis (PMID:12668280)
• data suggest that endothelial differentiation gene EDG-7 regulates Lysophosphatidic acid(LPA)-mediated mesangial cell proliferation and suggest that EDG-7 and EDG-2 LPA receptors play a diverse role in mesangial cell proliferation (PMID:15292052)
• expression of LPA-induced inflammatory response genes is mediated by LPA1 and LPA3 (PMID:17923111)
• Lysophosphatidic acid receptor 3 may contribute to the pathogenesis of rheumatoid arthritis through the modulation of fibroblast-like synoviocyte migration and cytokine production. (PMID:18006645)
• Lysophosphatidic acid might regulate VEGF-C and lymphatic marker expression in endothelial cells, which contributes to endothelial cell tube formation in vitro and in vivo, thus facilitating endothelial cell participation lymphangiogenesis. (PMID:18627789)
• Expression of LPA3 during ovarian carcinogenesis contributes to ovarian cancer aggressiveness, suggesting that the targeting of LPA production and action may have potential for the treatment of ovarian cancer. (PMID:19001604)
• Switching of LPA receptor expression from LPA3 to LPA1, may be involved in prostate cancer progression and/or androgen independence (PMID:19025891)
• LPA(1) receptor, LPA(2) and LPA(3) receptors-induced VASP phosphorylation is a critical mediator of tumor cell migration initiation (PMID:19081821)
• LPA-stimulated cell growth is mediated by distinct but overlapping receptors and signaling pathways in these two model ovarian cancer cell lines. (PMID:19420982)
• Data show that CLL cells express LPA receptors LPA(1-5) and VEGF receptors, and the plasma levels of VEGF are elevated in CLL patients. (PMID:19860625)
• show that human microglia express LPA receptor subtypes LPA(1), LPA(2), and LPA(3) on mRNA and protein level. LPA activation of C13NJ cells induced Rho and extracellular signal-regulated kinase activation and enhanced cellular ATP production. (PMID:19899077)
• Mutation in LPA3 gene indicate that the alterations in LPA receptor gene may play some role in pathogenesis in human osteosarcoma cells. (PMID:21116120)
• found that LPA receptor 2/3-mediated IL-8 expression occurs through Gi/PI3K/AKT, Gi/PKC and IkappaB/NF-kappaB signaling (PMID:21964883)
• study found that LPS induces both ATX and LPA3 expression in THP-1 cells; the PKR and SPK1-mediated pathways are involved in both ATX and LPA3 induction, resulting in the coordinate up-regulation of these two genes (PMID:22314276)
• LPA3 Receptor act as a negative regulator on cell motile and invasive abilities of colon cancer. (PMID:22763559)
• in the normal human menstrual cycle, lysophosphatidic acid receptor 3 messenger RNA and protein expression change, indicating that this gene may be related to the function of the endometrium. (PMID:22872026)
• High LPAR3 expression is associated with aggressiveness of breast carcinoma. (PMID:22922883)
• The results indicated that LPA(3) acts as a positive regulator of cell motility and invasion in sarcoma cells, suggesting that LPA signaling pathway via LPA(3) may be involved in the progression of sarcoma cells. (PMID:23167620)
• Findings indicate lysophosphatidic acid (LPA)-lysophosphatidic acid receptor-Galpha13 signaling node as a therapeutic target for pancreatic cancer treatment and control. (PMID:23508014)
• Lysophosphatidic acid (LPA) increased hepatocellular carcinoma cells cell invasion, which was LPA-receptor dependent. (PMID:23569130)
• LPA3 mRNA is clearly expressed in human PANC-1 tumor cells. (PMID:24061591)
• The results demonstrate LPA-stimulated migration in oral carcinoma cells through LPAR3, mediated further by PKC, which acts either in concert with or independently of EGFR transactivation (PMID:24928086)
• These data indicated that the expression of LPA receptor 3 was increased in human triple-negative breast cancers and is associated with tumor metastatic ability. (PMID:25209561)
• Suggest that LPA2 and LPA3 may function as a molecular switch and play opposing roles during megakaryopoiesis of K562 cells. (PMID:25463482)
• Expression profiles reveal LPAR3 (lysophosphatidic acid receptor 3) as a mediator for mitotic phosphorylation-driven pancreatic cell motility and invasion. Together, this work identifies YAP as a novel regulator of pancreatic cancer cell motility, invasion and metastasis. (PMID:26440309)
• The results indicate that LPA2 and LPA3 receptors play opposing roles during red blood cells differentiation. (PMID:27244685)
• myeloma cells stimulate mesenchymal stem cells (MSCs to produce autotaxin, an indispensable enzyme for the biosynthesis of lysophosphatidic acid, and LPA receptor 1 (LPA1) and 3 (LPA3) transduce opposite signals to MSCs to determine the fate of MSCs. (PMID:27641212)
• Using pharmacological activators and shRNA knockdown experiments, we demonstrate that activation of LPA3 inhibits megakaryopoiesis in human HSCs. In addition, pharmacological activation of LPA3 suppressed thrombopoiesis in zebrafish. (PMID:29239275)
• Study also identifies that LPAR3 increases miR-122-5p expression, which occurs mechanistically through the SH3 domain and helps explain why miR-122-5p increases are detected in cancer patient serum. LPAR3 is partially responsible for the production and secretion of miR-122-5p, found in the serum of a wide variety of patients with cancer. (PMID:30266753)
• LPAR3 was differently expressed in melanosis coli tissues.LPAR3 expression was related to cell apoptosis. (PMID:30559147)
• Lysophosphatidic acid receptor LPA3 prevents oxidative stress and cellular senescence in Hutchinson-Gilford progeria syndrome. (PMID:31714004)
• Effects of lysophosphatidic acid (LPA) receptor-2 (LPA2) and LPA3 on the regulation of chemoresistance to anticancer drug in lung cancer cells. (PMID:32006610)
• The Agpat4/LPA axis in colorectal cancer cells regulates antitumor responses via p38/p65 signaling in macrophages. (PMID:32296017)
• Roles of endothelial cells in the regulation of cell motility via lysophosphatidic acid receptor-2 (LPA2) and LPA3 in osteosarcoma cells. (PMID:33347862)
• Transcriptional regulation of lysophosphatidic acid receptors 2 and 3 regulates myeloid commitment of hematopoietic stem cells. (PMID:33406026)
• LPAR1 and aberrantly expressed LPAR3 differentially promote the migration and proliferation of malignant peripheral nerve sheath tumor cells. (PMID:36416236)
• LPA3 Receptor Phosphorylation Sites: Roles in Signaling and Internalization. (PMID:38791546)
• Lysophosphatidic Acid Receptor 3 (LPA3): Signaling and Phosphorylation Sites. (PMID:38928196)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	lpar3	ENSDARG00000101814
mus_musculus	Lpar3	ENSMUSG00000036832
rattus_norvegicus	Lpar3	ENSRNOG00000064204

Paralogs (18): LPAR2 (ENSG00000064547), CNR1 (ENSG00000118432), MC3R (ENSG00000124089), S1PR4 (ENSG00000125910), GPR12 (ENSG00000132975), GPR6 (ENSG00000146360), GPR119 (ENSG00000147262), MC4R (ENSG00000166603), S1PR1 (ENSG00000170989), MC5R (ENSG00000176136), S1PR5 (ENSG00000180739), GPR3 (ENSG00000181773), MC2R (ENSG00000185231), CNR2 (ENSG00000188822), LPAR1 (ENSG00000198121), S1PR3 (ENSG00000213694), MC1R (ENSG00000258839), S1PR2 (ENSG00000267534)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1929469) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 8 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal systemic arterial blood pressure	1
abnormal placenta morphology	1
impaired embryo implantation	1
decreased litter size	1
long gestation period	1
impaired spacing of implantation sites	1
delayed embryo implantation	1
decreased prostaglandin level	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Macaca fascicularis	Q95KH4	98.6%	Diamond
Xenopus laevis	Q9PU16	98.4%	Diamond
Ovis aries	P46628	97.8%	Diamond
Bos taurus	Q28031	97.8%	Diamond
Sus scrofa	Q684M3	86.7%	Diamond
Takifugu rubripes	Q9PUQ8	69.1%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
SSX2IP	protein-coding	117178
MCOLN2	protein-coding	255231
LINC01555	ncRNA	439927
LINC01461	ncRNA	103695366
DNAI3	protein-coding	126820
MCOLN3	protein-coding	55283
MIR4423	ncRNA	100616481

Protein

Protein identifiers

Lysophosphatidic acid receptor 3 — Q9UBY5 (reviewed: Q9UBY5)

Alternative names: Lysophosphatidic acid receptor Edg-7

All UniProt accessions (1): Q9UBY5

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. May play a role in the development of ovarian cancer. Seems to be coupled to the G(i)/G(o) and G(q) families of heteromeric G proteins.

Subcellular location. Cell membrane.

Tissue specificity. Most abundantly expressed in prostate, testes, pancreas, and heart, with moderate levels in lung and ovary. No detectable expression in brain, placenta, liver, skeletal muscle, kidney, spleen, thymus, small intestine, colon, or peripheral blood leukocytes.

Similarity. Belongs to the G protein-coupled receptor 1 family.

RefSeq proteins (1): NP_036284* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR004065	LPA_rcpt	Family
IPR005385	LPA_rcpt_EDG7	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain

Pfam: PF00001

UniProt features (20 total): topological domain 8, transmembrane region 7, glycosylation site 2, chain 1, lipid moiety-binding region 1, sequence variant 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UBY5-F1	81.63	0.47

Human Protein Atlas

Protein class: G-protein coupled receptors, GPCRs excl olfactory receptors, Lysolipids receptors, Predicted membrane proteins, GPCRHMM predicted membrane proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): plasma membrane; primary cilium

Antibody reliability (HPA): IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1)

Type	Positions
S-palmitoyl cysteine	309

Glycosylation sites (2)

Type	Positions
N-linked (glcnac…) asparagine	15, 172

Function

Pathways and Gene Ontology

Reactome pathways

3 curated (TAS) of 8; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

8 pathways:

ID	Pathway	Evidence
R-HSA-418594	G alpha (i) signalling events	curated
R-HSA-416476	G alpha (q) signalling events	curated
R-HSA-419408	Lysosphingolipid and LPA receptors	curated
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)	—
R-HSA-388396	GPCR downstream signalling	—
R-HSA-500792	GPCR ligand binding	—
R-HSA-162582	Signal Transduction	—
R-HSA-372790	Signaling by GPCR	—

MSigDB gene sets: 163 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, GOBP_POSITIVE_REGULATION_OF_CALCIUM_ION_TRANSPORT, GOBP_REGULATION_OF_COLLATERAL_SPROUTING, GOBP_REGULATION_OF_DEVELOPMENTAL_GROWTH, GOBP_GROWTH, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, GOBP_NEUROGENESIS, GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_ADENYLATE_CYCLASE_MODULATING_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_SIZE, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION

GO Biological Process (8): G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger (GO:0007187), adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189), positive regulation of cytosolic calcium ion concentration (GO:0007204), chemical synaptic transmission (GO:0007268), gene expression (GO:0010467), positive regulation of calcium ion transport (GO:0051928), signal transduction (GO:0007165), G protein-coupled receptor signaling pathway (GO:0007186)

GO Molecular Function (6): G-protein alpha-subunit binding (GO:0001965), G protein-coupled receptor activity (GO:0004930), phospholipid binding (GO:0005543), lipid binding (GO:0008289), lysophosphatidic acid receptor activity (GO:0070915), protein binding (GO:0005515)

GO Cellular Component (5): cytoplasm (GO:0005737), plasma membrane (GO:0005886), axon (GO:0030424), synapse (GO:0045202), membrane (GO:0016020)

Reactome top-level categories

5 top-level categories:

Category	Pathways
GPCR downstream signalling	2
Signaling by GPCR	2
Class A/1 (Rhodopsin-like receptors)	1
Signal Transduction	1
GPCR ligand binding	1

GO top-level categories

28 GO namespaces:

Category	Terms
G protein-coupled receptor signaling pathway	2
binding	2
cellular anatomical structure	2
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
adenylate cyclase activator activity	1
regulation of biological quality	1
anterograde trans-synaptic signaling	1
macromolecule biosynthetic process	1
calcium ion transport	1
positive regulation of monoatomic ion transport	1
regulation of calcium ion transport	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
protein binding	1
transmembrane signaling receptor activity	1
lipid binding	1
lysophosphatidic acid binding	1
bioactive lipid receptor activity	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
neuron projection	1
cell junction	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 1 of 19 annotations. The rest are phylogenetic / computational / electronic (IEA).

1 experimentally-supported GO terms:

GO term	NS	Evidence
plasma membrane	CC	direct assay

Protein interactions and networks

STRING

showing 15 of 652 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LPAR3	LPAR6	P43657	934
LPAR3	LIPH	Q8WWY8	883
LPAR3	LPAR5	Q9H1C0	882
LPAR3	LPAR4	Q99677	881
LPAR3	ENPP2	Q13822	767
LPAR3	POU2F3	Q9UKI9	697
LPAR3	GDPD1	Q8N9F7	654
LPAR3	PLA1A	Q53H76	635
LPAR3	GDPD3	Q7L5L3	629
LPAR3	GPR87	Q9BY21	623
LPAR3	LIPG	Q9Y5X9	612
LPAR3	RPA3	P35244	601
LPAR3	PTGS2	P35354	585
LPAR3	P2RY10	O00398	540
LPAR3	PLA2G4A	P47712	536

IntAct

Human interaction partners of LPAR3 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

showing 30 of 53 partners by confidence:

Partner	Interaction type	MIscore	Records
CD74	physical association	0.600	4
CREB3L1	physical association	0.560	5
RETREG3	physical association	0.560	5
AQP6	physical association	0.560	3
ARL13B	physical association	0.560	3
ASZ1	physical association	0.560	3
BCL2L13	physical association	0.560	3
C16orf54	physical association	0.560	3
CD53	physical association	0.560	3
CD79A	physical association	0.560	3
CLDN2	physical association	0.560	3
CLDN7	physical association	0.560	3
CLDN9	physical association	0.560	3
CLEC12B	physical association	0.560	3
CPLX4	physical association	0.560	3
CYB561	physical association	0.560	3
CYBRD1	physical association	0.560	3
EDA	physical association	0.560	3
ERGIC3	physical association	0.560	3
FAM209A	physical association	0.560	3
FFAR2	physical association	0.560	3
FNDC9	physical association	0.560	3
GJB5	physical association	0.560	3
GORAB	physical association	0.560	3
GPX8	physical association	0.560	3
JAGN1	physical association	0.560	3
KCNC1	physical association	0.560	3
KCNJ6	physical association	0.560	3
LEPROTL1	physical association	0.560	3
LHFPL5	physical association	0.560	3

BioGRID (67 interactions; top human partners by supporting records): APP (Reconstituted Complex), AQP6 (Two-hybrid), ARL13B (Two-hybrid), ASZ1 (Two-hybrid), BCL2L13 (Two-hybrid), C16orf54 (Two-hybrid), CD53 (Two-hybrid), CD74 (Two-hybrid), CD79A (Two-hybrid), CDC123 (Affinity Capture-MS), CHRNA4 (Affinity Capture-MS), CLDN2 (Two-hybrid), CLDN7 (Two-hybrid), CLDN9 (Two-hybrid), CLEC12B (Two-hybrid)

SIGNOR signaling

showing 15 of 19 signaling interactions:

A	Effect	B	Mechanism
LPAR3	up-regulates	GNA12	binding
LPAR3	up-regulates	GNA13	binding
“lysophosphatidic acids”	up-regulates	LPAR3	“chemical activation”
“3-[({4-[4-({[1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid”	down-regulates	LPAR3	“chemical inhibition”
LPAR3	“up-regulates activity”	GNAL	binding
LPAR3	“up-regulates activity”	GNAI1	binding
LPAR3	“up-regulates activity”	GNAI3	binding
LPAR3	“up-regulates activity”	GNAO1	binding
LPAR3	“up-regulates activity”	GNAZ	binding
LPAR3	“up-regulates activity”	GNAQ	binding
LPAR3	“up-regulates activity”	GNA14	binding
LPAR3	“up-regulates activity”	GNA15	binding
“lysophosphatidic acid”	“up-regulates activity”	LPAR3	“chemical activation”
LPAR3	up-regulates	GNAI1	binding
LPAR3	up-regulates	GNAQ	binding

Protein complexes (CORUM) (8)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

8 complexes by size:

Complex	Subunits	Members
LPAR1-LPAR3 complex	2	LPAR1, LPAR3
LPAR2-LPAR3 complex	2	LPAR2, LPAR3
★ LPAR3-S1PR1 complex	2	LPAR3, S1PR1
LPAR3-S1PR2 complex	2	LPAR3, S1PR2
★ LPAR3-S1PR3 complex	2	LPAR3, S1PR3
GPR4-LPAR3 complex	2	GPR4, LPAR3
GPR68-LPAR3 complex	2	GPR68, LPAR3
Lysophosphatidic acid receptor 3	1	LPAR3

Ligand–receptor pairs (CellPhoneDB) (1)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

1 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
ADGRE5	ligand	Signaling by Lysophosphatidic acid receptor

Disease & clinical

Genetic variants

Variant evidence for LPAR3: 69 ClinVar records (0 pathogenic / likely pathogenic); 10 GWAS associations.

ClinVar

69 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	61
Likely benign	0
Benign	3

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 27 predictions of 434):

Position(s)	Effect	Δscore	Sites
1:84814172–84814173	acceptor_loss	1.0000	2
1:84893014–84893015	donor_loss	1.0000	5
1:84814172–84814173	acceptor_loss	0.9900	4
1:84859232	donor_gain	0.9900
1:84814176	acceptor_gain	0.9800
1:84837424	donor_gain	0.9800
1:84865383–84865384	donor_loss	0.9800	6
1:84866026	donor_gain	0.9700
1:84866139–84866140	acceptor_loss	0.9600	5
1:84866139	acceptor_loss	0.9500

AlphaMissense

1,053 missense substitutions predicted likely pathogenic (of 2,349 scored), across 243 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M202	9	0.887	0.994
M300	9	0.845	0.967
D76	8	0.998	0.999
N48	8	0.987	0.998
N289	8	0.986	0.998
F248	8	0.981	0.999
D262	8	0.978	0.986
D297	8	0.974	0.991
N285	8	0.965	0.998
D110	8	0.960	0.982
F61	8	0.938	0.997
F199	8	0.935	0.983
H62	8	0.911	0.986
F65	8	0.877	0.987
N58	8	0.780	0.951
C169	7	0.993	0.998
C176	7	0.993	0.997
W252	7	0.993	0.999
W153	7	0.986	0.999
W167	7	0.985	0.998

HPA cancer prognostics

RNA cancer specificity: Cancer enhanced (Ovary Serous Cystadenocarcinoma)

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

2 prognostic cancer types:

Cancer	Prognostic	p-value
Ovary Serous Cystadenocarcinoma (TCGA)	favorable	0.000489
Bladder Urothelial Carcinoma (TCGA)	unfavorable	0.000911

Disease associations

OMIM: gene MIM:605106 | disease phenotypes:

GWAS associations

10 associations:

Study	Trait	p-value
GCST006979_764	Heel bone mineral density	1e-12
GCST006979_763	Heel bone mineral density	3e-11
GCST004490_13	Cerebrospinal fluid t-tau:AB1-42 ratio	2e-8
GCST012490_435	Femur bone mineral density x serum urate levels interaction	3e-8
GCST000244_4	Type 1 diabetes	2e-6
GCST001713_22	Dental caries	2e-6
GCST001726_4	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	4e-6
GCST002726_32	Glucose homeostasis traits	6e-6
GCST003254_10	Urinary albumin-to-creatinine ratio in non-diabetics	7e-6
GCST001511_10	Economic and political preferences (time)	9e-6

EFO canonical traits (from GWAS)

7 canonical traits:

EFO ID	Trait name
EFO:0004827	economic and social preference
EFO:0004746	lipoprotein-associated phospholipase A(2) measurement
EFO:0004471	insulin sensitivity measurement
EFO:0007778	urinary albumin to creatinine ratio
EFO:0007708	t-tau:beta-amyloid 1-42 ratio measurement
EFO:0009270	heel bone mineral density
EFO:0004531	urate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3250 (SINGLE PROTEIN), CHEMBL3885601 (PROTEIN FAMILY)

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Lysophospholipid (LPA) receptors

Most potent curated ligand interactions (21 total), top 21:

Ligand	Action	Affinity	Parameter
T13	Agonist	9.3	pEC50
α-fluoromethylenephosphonate	Agonist	9.3	pEC50
2-oleoyl-LPA	Agonist	8.0	pEC50
dodecyl-thiophosphate	Antagonist	7.89	pKi
CpY	Agonist	7.7	pEC50
alkyl OMPT	Agonist	7.21	pEC50
CpX	Agonist	7.2	pEC50
OMPT	Agonist	7.17	pEC50
dodecylphosphate	Antagonist	7.05	pKi
dioctanoylglycerol pyrophosphate	Agonist	6.97	pIC50
farnesyl diphosphate	Antagonist	6.81	pKd
VPC32183	Antagonist	6.76	pIC50
LPA	Agonist	6.69	pKd
Ki16425	Antagonist	6.44	pKi
VPC12249	Antagonist	6.37	pIC50
farnesyl monophosphate	Antagonist	6.3	pIC50
oleoyl-thiophosphate	Partial agonist	6.26	pEC50
H2L5186303	Antagonist	5.91	pIC50
AM966	Antagonist	5.7	pIC50
compound 12 [PMID: 19800804]	Antagonist	5.52	pIC50
NAEPA	Agonist	5.3	pEC50

Binding affinities (BindingDB)

146 measured of 201 human assays (201 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
CHEMBL4871014	IC50	1 nM
CHEMBL3975893	IC50	3.5 nM
1-[4-[6-[5-[[6-(cyclopropoxy)pyrazin-2-yl]amino]-1-methyl-pyrazol-4-yl]-5-fluoro-3-pyridyl]phenyl]cyclopropanecarboxylic Acid; Hydrochloride	IC50	8.61 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[4-[6-[5-[[6-(cyclopropoxy)pyrazin-2-yl]amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]phenyl]cyclopropanecarboxylic Acid	IC50	9.86 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
CHEMBL2335047	EC50	10 nM
CHEMBL2335050	EC50	11 nM
1-[4-[5-fluoro-6-[5-[(6-isopropoxypyrazin-2-yl)amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]phenyl]cyclopropanecarboxylic Acid; Hydrochloride	IC50	11.1 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
CHEMBL2335051	EC50	12 nM
(R)—N-(1-(1-(1H-indazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide	IC50	14 nM
CHEMBL357053	EC50	15 nM
1-[4-[5-fluoro-6-[5-[[6-(1-fluoro-1-methyl-ethyl)pyrazin-2-yl]amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]phenyl]cyclopropanecarboxylic Acid Hydrochloride	IC50	16.7 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[4-[4-[1-methyl-5-[[(1R)-1-[3-(trifluoromethyl)phenyl]ethoxy]carbonylamino]triazol-4-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid	IC50	17 nM	US-9321738: N-alkyltriazole compounds as LPAR antagonists
1-[4-[6-[5-[[6-(cyclobutoxy)pyrazin-2-yl]amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]phenyl]cyclopropanecarboxylic Acid	IC50	17.2 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[2-cyano-4-[6-[5-[[6-(cyclopropoxy)pyrazin-2-yl]amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]phenyl]cyclopropanecarboxylic Acid; Hydrochloride	IC50	17.9 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[4-[3-fluoro-4-[1-methyl-5-[[(1R)-1-phenylethoxy]carbonylamino]triazol-4-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid	IC50	18 nM	US-9321738: N-alkyltriazole compounds as LPAR antagonists
1-[4-[4-[1-methyl-5-[[(1R)-1-phenylethoxy]carbonylamino]triazol-4-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid	IC50	18 nM	US-9321738: N-alkyltriazole compounds as LPAR antagonists
[(1R)-1-phenylethyl] N-[3-methyl-5-[4-[4-[1-(methylsulfonylcarbamoyl)cyclopropyl]phenyl]phenyl]triazol-4-yl]carbamate	IC50	18.8 nM	US-9321738: N-alkyltriazole compounds as LPAR antagonists
CHEMBL1222042	IC50	20 nM
CHEMBL2182063	IC50	20 nM
1-[4-[6-[1-methyl-5-[(6-propan-2-ylpyrazin-2-yl)amino]pyrazol-4-yl]-3-pyridinyl]phenyl]cyclopropane-1-carboxylic acid	IC50	20.6 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[4-[6-[5-[[6-(cyclopropoxy)pyrazin-2-yl]amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]-2-(trifluoromethyl)phenyl]cyclopropanecarboxylic Acid; Hydrochloride	IC50	22 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[4-[4-[5-[(6-isopropylpyrazin-2-yl)amino]-1-methyl-pyrazol-4-yl]phenyl]phenyl]cyclopropanecarboxylic Acid	IC50	23.6 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
2-(2-(2-aminoacetamido)-3-(2,4-dinitrophenylthio)propanamido)pentanedioic acid	IC50	24 nM
[(1R)-1-[3-(trifluoromethyl)phenyl]ethyl] N-[3-methyl-5-[4-[4-[1-(methylsulfonylcarbamoyl)cyclopropyl]phenyl]phenyl]triazol-4-yl]carbamate	IC50	24 nM	US-9321738: N-alkyltriazole compounds as LPAR antagonists
CHEMBL2182064	IC50	24 nM
CHEMBL153043	EC50	24 nM
1-[4-[2-[5-[(6-isopropylpyrazin-2-yl)amino]-1-methyl-pyrazol-4-yl]pyrimidin-5-yl]phenyl]cyclopropanecarboxylic acid	IC50	24 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[4-[6-[5-[[6-(1,1-difluoroethyl)pyrazin-2-yl]amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]phenyl]cyclopropanecarboxylic Acid; Hydrochloride	IC50	24.4 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
CHEMBL2335049	EC50	26 nM
1-[4-[6-[5-[[6-(3,3-difluorocyclobutoxy)pyrazin-2-yl]amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]phenyl]cyclopropanecarboxylic Acid	IC50	26.9 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[4-[6-[5-[(6-isopropoxypyrazin-2-yl)amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]-2-methyl-phenyl]cyclopropanecarboxylic Acid; Hydrochloride	IC50	27.1 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
3-[4’-(3-Carboxy-acryloylamino)-biphenyl-4-ylcarbamoyl]-acrylic acid	IC50	28.3 nM
1-[3-cyano-4-[6-[5-[(6-isopropylpyrazin-2-yl)amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]phenyl]cyclopropanecarboxylic Acid; Hydrochloride	IC50	29.3 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[4-[6-[5-[(6-isopropoxypyrazin-2-yl)amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]phenyl]cyclopropanecarboxylic Acid; Hydrochloride	IC50	29.3 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[3-methyl-4-[6-[1-methyl-5-[(6-propan-2-ylpyrazin-2-yl)amino]pyrazol-4-yl]-3-pyridinyl]phenyl]cyclopropane-1-carboxylic acid	IC50	30.9 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
CHEMBL2335048	EC50	31 nM
CHEMBL2182061	IC50	35 nM
1-[4-[6-[1-methyl-5-[[6-(trifluoromethyl)pyrazin-2-yl]amino]pyrazol-4-yl]-3-pyridyl]phenyl]cyclopropanecarboxylic Acid	IC50	36.3 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
(3-Octadec-9-enoylamino-propionyl)-phosphonothioic acid	EC50	40 nM
CHEMBL2182023	IC50	41 nM
1-[3-(cyanomethyl)-4-[6-[5-[(6-isopropylpyrazin-2-yl)amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]phenyl]cyclopropanecarboxylic Acid; Hydrochloride	IC50	42.9 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[4-[6-[5-[[6-(1-fluoro-1-methyl-ethyl)pyrazin-2-yl]amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]phenyl]cyclopropanecarboxylic Acid; Hydrochloride	IC50	44 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[4-[6-[5-[(6-isopropylpyrazin-2-yl)amino]-1-methyl-pyrazol-4-yl]-3-pyridyl]-3-(methoxymethyl)phenyl]cyclopropanecarboxylic Acid; Hydrochloride	IC50	45.8 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[4-[4-[1-methyl-5-[1-[3-(trifluoromethyl)phenyl]ethoxycarbonylamino]triazol-4-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid	IC50	46 nM	US-9321738: N-alkyltriazole compounds as LPAR antagonists
1-[6-[6-[1-methyl-5-[(6-propan-2-ylpyrazin-2-yl)amino]pyrazol-4-yl]-3-pyridinyl]-3-pyridinyl]cyclopropane-1-carboxylic acid	IC50	48 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
CHEMBL404575	IC50	50 nM
1-[4-[4-[5-[(6-chloropyrazin-2-yl)amino]-1-methylpyrazol-4-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid	IC50	52.9 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
1-[4-[4-[1-methyl-5-[[6-(2-methylpropyl)pyrazin-2-yl]amino]pyrazol-4-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid	IC50	54.7 nM	US-11365185: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
CHEMBL2182065	IC50	57 nM
Phosphoric acid mono-[2-((Z)-octadec-9-enoylamino)-ethyl] ester	IC50	60 nM

ChEMBL bioactivities

209 potent at pChembl≥5 of 220 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.69	EC50	0.2042	nM	CHEMBL2335051
9.68	EC50	0.21	nM	CHEMBL2335051
9.65	EC50	0.2239	nM	CHEMBL2335052
9.64	EC50	0.23	nM	CHEMBL2335052
9.57	EC50	0.27	nM	CHEMBL357053
9.57	EC50	0.2692	nM	CHEMBL357053
9.56	EC50	0.2754	nM	CHEMBL2017139
9.55	EC50	0.28	nM	CHEMBL2017139
9.44	EC50	0.36	nM	CHEMBL2335049
9.44	EC50	0.3631	nM	CHEMBL2335049
9.43	EC50	0.37	nM	CHEMBL2335047
9.43	EC50	0.3715	nM	CHEMBL2335047
9.41	EC50	0.39	nM	CHEMBL2335050
9.40	EC50	0.3981	nM	CHEMBL2335050
9.36	EC50	0.44	nM	CHEMBL153043
9.35	EC50	0.4467	nM	CHEMBL153043
8.97	EC50	1.08	nM	CHEMBL2335048
8.97	EC50	1.072	nM	CHEMBL2335048
8.52	EC50	3	nM	CHEMBL201482
8.30	Ki	5	nM	CHEMBL202361
7.96	IC50	11	nM	CHEMBL202361
7.85	Ki	14	nM	THIOPHOSPHORIC ACID DODECYL ESTER
7.85	Ki	14	nM	CHEMBL190484
7.85	Ki	14	nM	CHEMBL187402
7.62	IC50	24	nM	CHEMBL2372286
7.57	Ki	27	nM	CHEMBL190349
7.57	IC50	27	nM	CHEMBL190484
7.55	IC50	28	nM	THIOPHOSPHORIC ACID DODECYL ESTER
7.55	IC50	28	nM	CHEMBL187402
7.52	IC50	30	nM	CHEMBL485119
7.50	IC50	32	nM	CHEMBL190349
7.45	IC50	35.6	nM	CHEMBL91058
7.41	Ki	39	nM	CHEMBL183143
7.41	Ki	39	nM	CHEMBL362053
7.41	Ki	39	nM	CHEMBL202185
7.40	Ki	40	nM	CHEMBL188591
7.40	IC50	40	nM	CHEMBL272087
7.32	Ki	48	nM	CHEMBL183221
7.32	Ki	48	nM	CHEMBL3218459
7.31	Ki	49	nM	THIOPHOSPHORIC ACID DECYL ESTER
7.30	Ki	50	nM	CHEMBL203986
7.30	IC50	49.6	nM	CHEMBL5907737
7.24	Ki	58	nM	CHEMBL190430
7.21	EC50	62	nM	CHEMBL3621961
7.19	IC50	65	nM	CHEMBL2182050
7.18	IC50	65.7	nM	CHEMBL2182050
7.17	Ki	67	nM	CHEMBL427017
7.12	Ki	76	nM	THIOPHOSPHORIC ACID TETRADECYL ESTER
7.11	EC50	77	nM	LYSOPHOSPHATIDIC ACID
7.11	EC50	77.62	nM	LYSOPHOSPHATIDIC ACID

PubChem BioAssay actives

173 with measured affinity, of 471 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
dihydroxy-(2-methoxy-3-octadecoxypropoxy)-sulfanylidene-lambda5-phosphane	733690: Agonist activity at human LPA3 receptor transfected in HEK293 cells after 1 hr by TGFalpha shedding assay	ec50	0.0002	uM
sodium [1-[hydroxy(oxido)phosphinothioyl]oxy-3-methoxypropan-2-yl] octadecanoate	733690: Agonist activity at human LPA3 receptor transfected in HEK293 cells after 1 hr by TGFalpha shedding assay	ec50	0.0002	uM
[(2S)-3-dihydroxyphosphinothioyloxy-2-methoxypropyl] octadecanoate	733690: Agonist activity at human LPA3 receptor transfected in HEK293 cells after 1 hr by TGFalpha shedding assay	ec50	0.0003	uM
(3-dihydroxyphosphinothioyloxy-2-methoxypropyl) octadecanoate	733690: Agonist activity at human LPA3 receptor transfected in HEK293 cells after 1 hr by TGFalpha shedding assay	ec50	0.0003	uM
[(2R)-3-dihydroxyphosphinothioyloxy-2-methoxypropyl] octadecanoate	733690: Agonist activity at human LPA3 receptor transfected in HEK293 cells after 1 hr by TGFalpha shedding assay	ec50	0.0004	uM
sodium (2-hexadecoxy-3-methoxypropoxy)-hydroxy-oxido-sulfanylidene-lambda5-phosphane	733690: Agonist activity at human LPA3 receptor transfected in HEK293 cells after 1 hr by TGFalpha shedding assay	ec50	0.0004	uM
sodium (2-heptadecoxy-3-methoxypropoxy)-hydroxy-oxido-sulfanylidene-lambda5-phosphane	733690: Agonist activity at human LPA3 receptor transfected in HEK293 cells after 1 hr by TGFalpha shedding assay	ec50	0.0004	uM
dihydroxy-[(2S)-2-methoxy-3-octadecoxypropoxy]-sulfanylidene-lambda5-phosphane	733690: Agonist activity at human LPA3 receptor transfected in HEK293 cells after 1 hr by TGFalpha shedding assay	ec50	0.0004	uM
dihydroxy-[(2R)-2-methoxy-3-octadecoxypropoxy]-sulfanylidene-lambda5-phosphane	733690: Agonist activity at human LPA3 receptor transfected in HEK293 cells after 1 hr by TGFalpha shedding assay	ec50	0.0011	uM
[(2R)-2,3-dioctoxypropoxy]-dihydroxy-sulfanylidene-lambda5-phosphane	260482: Activity at LPA3 receptor transfected RH7777 cells	ec50	0.0030	uM
[(2R)-3-dihydroxyphosphinothioyloxy-2-octanoyloxypropyl] octanoate	260482: Activity at LPA3 receptor transfected RH7777 cells	ki	0.0050	uM
dodecoxy-dihydroxy-sulfanylidene-lambda5-phosphane	239112: Binding affinity for Lysophosphatidic acid receptor 3 expressed in RH7777 rat hepatoma cells	ki	0.0140	uM
[(E)-dodec-9-enoxy]-dihydroxy-sulfanylidene-lambda5-phosphane	239112: Binding affinity for Lysophosphatidic acid receptor 3 expressed in RH7777 rat hepatoma cells	ki	0.0140	uM
dihydroxy-sulfanylidene-[(E)-tetradec-9-enoxy]-lambda5-phosphane	239112: Binding affinity for Lysophosphatidic acid receptor 3 expressed in RH7777 rat hepatoma cells	ki	0.0140	uM
(2S)-2-[[(2R)-2-[(2-aminoacetyl)amino]-3-(2,4-dinitrophenyl)sulfanylpropanoyl]amino]pentanedioic acid	408399: Antagonist activity at LPA3 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration	ic50	0.0240	uM
[(E)-dodec-9-enyl] dihydrogen phosphate	239112: Binding affinity for Lysophosphatidic acid receptor 3 expressed in RH7777 rat hepatoma cells	ki	0.0270	uM
2,6-bis[[(E)-3-carboxyprop-2-enoyl]amino]benzoic acid	408399: Antagonist activity at LPA3 receptor expressed in rat RH7777 cells assessed as inhibition of LPA-induced intracellular calcium concentration	ic50	0.0300	uM
[(2R)-3-[4-[(3-methoxyphenyl)methoxy]phenyl]-2-[[(Z)-octadec-9-enoyl]amino]propyl] dihydrogen phosphate	102985: In vitro antagonism of LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 3 in HEK293T cell lines	ic50	0.0356	uM
[(2R)-2-octanoyloxy-3-phosphonooxypropyl] octanoate	260482: Activity at LPA3 receptor transfected RH7777 cells	ki	0.0390	uM
[(2R)-3-[4-[(4-ethoxy-2-pyridinyl)methoxy]phenyl]-2-[[(Z)-octadec-9-enoyl]amino]propyl] dihydrogen phosphate	240661: Binding affinity towards Lysophosphatidic acid 3 (LPA3) receptor	ki	0.0390	uM
[(2R)-3-[4-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methoxy]phenyl]-2-[[(Z)-octadec-9-enoyl]amino]propyl] dihydrogen phosphate	240661: Binding affinity towards Lysophosphatidic acid 3 (LPA3) receptor	ki	0.0390	uM
[(E)-tetradec-11-enyl] dihydrogen phosphate	239112: Binding affinity for Lysophosphatidic acid receptor 3 expressed in RH7777 rat hepatoma cells	ki	0.0400	uM
2-[4-[[(3,5-dimethoxybenzoyl)-(3-phenylpropyl)amino]methyl]phenoxy]benzoic acid	320519: Antagonist activity at LPA3 expressed in RH7777 cells with Gi4-protein and aequorin by calcium mobilization assay	ic50	0.0400	uM
[(2R)-2-[[(Z)-octadec-9-enoyl]amino]-3-[4-[[4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methoxy]phenyl]propyl] dihydrogen phosphate	240661: Binding affinity towards Lysophosphatidic acid 3 (LPA3) receptor	ki	0.0480	uM
[(2R)-2-(octadecanoylamino)-3-[4-[[4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methoxy]phenyl]propyl] dihydrogen phosphate	1118228: Competitive antagonist activity at N-terminal 3XHA-tagged human LPA3 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation counting	ki	0.0480	uM
decoxy-dihydroxy-sulfanylidene-lambda5-phosphane	239112: Binding affinity for Lysophosphatidic acid receptor 3 expressed in RH7777 rat hepatoma cells	ki	0.0490	uM
sodium 1-[4-[4-[3-[1-(2-chlorophenyl)ethoxycarbonylamino]furo[2,3-c]pyridin-2-yl]phenyl]phenyl]cyclopropane-1-carboxylate	1938508: Antagonist activity at human LPA3 receptor	ec50	0.0500	uM
sodium 1-[4-[4-[3-(1-phenylethoxycarbonylamino)furo[2,3-c]pyridin-2-yl]phenyl]phenyl]cyclopropane-1-carboxylate	1938508: Antagonist activity at human LPA3 receptor	ec50	0.0500	uM
[(2S)-2,3-dioctoxypropyl] dihydrogen phosphate	260482: Activity at LPA3 receptor transfected RH7777 cells	ki	0.0500	uM
2-[7-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-1,2-oxazol-5-yl]phenyl]-2,3-dihydro-1H-inden-4-yl]acetic acid	1938508: Antagonist activity at human LPA3 receptor	ec50	0.0500	uM
[(E)-tetradec-9-enyl] dihydrogen phosphate	239112: Binding affinity for Lysophosphatidic acid receptor 3 expressed in RH7777 rat hepatoma cells	ki	0.0580	uM
[(1R)-1-[3-(trifluoromethyl)phenyl]ethyl] N-[3-methyl-5-[4-[4-[1-(methylsulfonylcarbamoyl)cyclopropyl]phenyl]phenyl]triazol-4-yl]carbamate	706181: Antagonist activity at human recombinant LPA3 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay	ic50	0.0650	uM
[(2S)-2,3-dioctoxypropoxy]-dihydroxy-sulfanylidene-lambda5-phosphane	260482: Activity at LPA3 receptor transfected RH7777 cells	ki	0.0670	uM
dihydroxy-sulfanylidene-tetradecoxy-lambda5-phosphane	239112: Binding affinity for Lysophosphatidic acid receptor 3 expressed in RH7777 rat hepatoma cells	ki	0.0760	uM
[(2R)-2-hydroxy-3-phosphonooxypropyl] (Z)-octadec-9-enoate	733690: Agonist activity at human LPA3 receptor transfected in HEK293 cells after 1 hr by TGFalpha shedding assay	ec50	0.0770	uM
[(2R)-3-[4-[(4-methoxy-2-pyridinyl)methoxy]phenyl]-2-[[(Z)-octadec-9-enoyl]amino]propyl] dihydrogen phosphate	240661: Binding affinity towards Lysophosphatidic acid 3 (LPA3) receptor	ki	0.1020	uM
[(2S)-3-dihydroxyphosphinothioyloxy-2-octanoyloxypropyl] octanoate	260482: Activity at LPA3 receptor transfected RH7777 cells	ec50	0.1150	uM
N-[(2S)-3-dihydroxyphosphinothioyloxy-1-(octylamino)-1-oxopropan-2-yl]octanamide	260482: Activity at LPA3 receptor transfected RH7777 cells	ki	0.1170	uM
N-[(2R)-3-dihydroxyphosphinothioyloxy-1-(octylamino)-1-oxopropan-2-yl]octanamide	260482: Activity at LPA3 receptor transfected RH7777 cells	ki	0.1180	uM
[(2S)-2-octanoyloxy-3-phosphonooxypropyl] octanoate	260482: Activity at LPA3 receptor transfected RH7777 cells	ki	0.1190	uM
decyl dihydrogen phosphate	239112: Binding affinity for Lysophosphatidic acid receptor 3 expressed in RH7777 rat hepatoma cells	ki	0.1210	uM
dodecyl dihydrogen phosphate	239112: Binding affinity for Lysophosphatidic acid receptor 3 expressed in RH7777 rat hepatoma cells	ki	0.1210	uM
dec-9-enoxy-dihydroxy-sulfanylidene-lambda5-phosphane	239112: Binding affinity for Lysophosphatidic acid receptor 3 expressed in RH7777 rat hepatoma cells	ki	0.1280	uM
1-[4-[4-[1-methyl-5-[[(1R)-1-[3-(trifluoromethyl)phenyl]ethoxy]carbonylamino]triazol-4-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid	706181: Antagonist activity at human recombinant LPA3 expressed in chem-1 cells assessed as inhibition of LPA-induced intracellular calcium mobilization incubated for 30 mins prior to LPA-challenge measured over 100 secs by FLIPR assay	ic50	0.1320	uM
[(2R)-2-heptanoyloxy-3-phosphonooxypropyl] heptanoate	408407: Inhibition of LPA3 receptor	ic50	0.1430	uM
3-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-1,2-oxazol-5-yl]phenyl]methylsulfanyl]propanoic acid	239112: Binding affinity for Lysophosphatidic acid receptor 3 expressed in RH7777 rat hepatoma cells	ki	0.1480	uM
[(3R)-4-[4-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methoxy]phenyl]-3-[[(Z)-octadec-9-enoyl]amino]butyl]phosphonic acid	240661: Binding affinity towards Lysophosphatidic acid 3 (LPA3) receptor	ki	0.1500	uM
[(2R)-2,3-dioctoxypropyl] dihydrogen phosphate	260482: Activity at LPA3 receptor transfected RH7777 cells	ec50	0.1640	uM
[(2R)-2-[[(Z)-octadec-9-enoyl]amino]-3-[4-(pyridin-2-ylmethoxy)phenyl]propyl] dihydrogen phosphate	102985: In vitro antagonism of LPA-evoked [35S]GTP-gamma-S binding to lysophosphatidic acid receptor 3 in HEK293T cell lines	ic50	0.1750	uM
[(2R)-3-dihydroxyphosphinothioyloxy-2-heptanoyloxypropyl] heptanoate	408407: Inhibition of LPA3 receptor	ic50	0.1840	uM

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	6
trichostatin A	affects cotreatment, increases expression	3
sodium arsenite	affects methylation, increases expression	3
bisphenol A	decreases expression, increases expression	2
mercuric bromide	decreases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
Benzo(a)pyrene	increases methylation, affects methylation	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
Tretinoin	decreases expression	2
Aflatoxin B1	decreases expression, decreases methylation	2
FR900359	decreases phosphorylation	1
quercitrin	increases expression	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	affects methylation, increases abundance	1
potassium chromate(VI)	increases expression	1
nickel sulfate	increases expression	1
lysophosphatidic acid	affects binding, decreases reaction, increases activity	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	1
dorsomorphin	affects cotreatment, increases expression, decreases expression	1
Sunitinib	decreases expression	1
Vorinostat	increases expression	1
Acetaminophen	decreases expression	1
Glyphosate	increases expression, decreases expression	1
Arsenic	affects methylation	1
Cadmium	decreases expression, increases abundance	1
Cannabinoids	affects methylation, increases abundance	1
Bucladesine	affects cotreatment, increases expression	1
Estradiol	increases expression, affects cotreatment	1
Progesterone	increases expression	1

ChEMBL screening assays

74 unique, capped per target: 56 functional, 18 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1064668	Functional	Agonist activity at LPA3 receptor expressed in rat RH7777 cells assessed as effect on intracellular calcium response at 10 uM	Structure-based drug design identifies novel LPA3 antagonists. — *Bioorg Med Chem*
CHEMBL1064670	Binding	Binding affinity to LPA3	Structure-based drug design identifies novel LPA3 antagonists. — *Bioorg Med Chem*

Cellosaurus cell lines

8 cell lines: 4 cancer cell line, 3 transformed cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3A9	Abcam HEK293T LPAR3 KO	Transformed cell line	Female
CVCL_D8PD	Ubigene HCT 116 LPAR3 KO	Cancer cell line	Male
CVCL_D9IQ	Ubigene HEK293 LPAR3 KO	Transformed cell line	Female
CVCL_KW98	PathHunter CHO-K1 EDG7 beta-arrestin	Spontaneously immortalized cell line	Female
CVCL_LA25	PathHunter U2OS EDG7 Activated GPCR Internalization	Cancer cell line	Female
CVCL_XA29	GeneBLAzer EDG7-NFAT-bla HEK 293T	Transformed cell line	Female
CVCL_YK53	U2OS LPAR3 HiTSeeker	Cancer cell line	Female
CVCL_ZK32	Tango EDG7-bla U2OS	Cancer cell line	Female

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for LPAR3 across ~30M SureChEMBL compounds — explore on Sugi Predict.